Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AZD4625 is a Potent and Selective Inhibitor of KRASG12C.

Molecular cancer therapeutics - 7 Oct 2022

Chakraborty Atanu, Hanson Lyndsey, Robinson David, Lewis Hilary, Bickerton Sue, Davies Michael, Polanski Radoslaw, Whiteley Rebecca, Koers Alex, Atkinson James, Baker Tamara, Del Barco Barrantes Ivan, Ciotta Giovanni, Kettle Jason G, Magiera Lukasz, Martins Carla P, Peter Alison, Wigmore Eleanor, Underwood Zoe, Cosulich Sabina, Niedbala Michael, Ross Sarah

Abstract excerpt

AZD4625 is a potent, selective, and orally bioavailable inhibitor of oncogenic KRASG12C as demonstrated in cellular assays and in vivo in preclinical cell line-derived and patient-derived xenograft models. In vitro and cellular assays have shown selective binding and inhibition of the KRASG12C mutant isoform, which carries a glycine to cysteine mutation at residue 12, with no binding and inhibition of wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Glycine

Share to Mutation

Share to Protein Isoforms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 35930755
DOI: 10.1158/1535-7163.MCT-22-0241
PMCID: PMC9538594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AZD4625 is a Potent and Selective Inhibitor of KRASG12C.PMID 35930755Read ↗

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C.Semantic proximity Read ↗

Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.Semantic proximity Read ↗

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.Semantic proximity Read ↗

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.Semantic proximity Read ↗

The KRASG12D Inhibitor Pipeline Grows.Semantic proximity Read ↗

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.Semantic proximity Read ↗

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models.Semantic proximity Read ↗

KRAS G12D can be targeted by potent salt-bridge forming inhibitorsSemantic proximity Read ↗

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.Semantic proximity Read ↗

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.Semantic proximity Read ↗

Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.Semantic proximity Read ↗

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.